NCT06746766

Brief Summary

This study aims to determine the participation rate of patients with registered rare cancers in clinical research.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
19mo left

Started Nov 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress48%
Nov 2024Dec 2027

Study Start

First participant enrolled

November 18, 2024

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

December 9, 2024

Completed
15 days until next milestone

First Posted

Study publicly available on registry

December 24, 2024

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

April 30, 2026

Status Verified

April 1, 2026

Enrollment Period

3 years

First QC Date

December 9, 2024

Last Update Submit

April 27, 2026

Conditions

Rare Cancer

Keywords

Rare Cancer

Outcome Measures

Primary Outcomes (1)

  • Establish a registry

    Establish a registry of rare cancer patients visiting the institution

    1 year

Secondary Outcomes (1)

  • Clinical trial registration rate (%)

    1 year

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Data collection includes: * Clinical characteristics (diagnosis, treatment information, primary/metastatic sites, staging, gender/age) * Survival information (diagnosis date, recurrence date, death date, disease progression) * Pathological information (diagnosis, genomic information)

You may qualify if:

  • Adults aged ≥19 years
  • Confirmed rare cancer
  • Life expectancy ≥3 months

You may not qualify if:

  • Serious or unstable medical/psychiatric conditions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Severance Hospital

Seoul, 03722, South Korea

RECRUITING

Related Publications (3)

  • Gatta G, Capocaccia R, Trama A, Martinez-Garcia C; RARECARE Working Group. The burden of rare cancers in Europe. Adv Exp Med Biol. 2010;686:285-303. doi: 10.1007/978-90-481-9485-8_17.

    PMID: 20824452BACKGROUND

  • Very rare cancers--a problem neglected. Lancet Oncol. 2001 Apr;2(4):189. doi: 10.1016/s1470-2045(00)00273-4. No abstract available.

    PMID: 11905758BACKGROUND

  • Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, Stiller CA, Coebergh JW. Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer. 2006 Sep;42(13):2183-90. doi: 10.1016/j.ejca.2006.06.006.

    PMID: 16919780BACKGROUND

Study Officials

  • Hyo Song Kim, MD, Ph.D

    Yonsei Cencer center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Hyo Song Kim, MD, Ph.D

CONTACT

82-2-2228-8124hyosong77@yuhs.ac

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 9, 2024

First Posted

December 24, 2024

Study Start

November 18, 2024

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

April 30, 2026

Record last verified: 2026-04

Locations

KR(1)